Search results for: Cyclosporine A





Formulation Characteristics and In Vitro Release Testing of Cyclosporine Ophthalmic Ointments.
The aim of the present study was to investigate the relationship between formulation/process variables versus the critical quality attributes (CQAs) of cyclosporine ophthalmic ointments and to explore the feasibility of using an in vitro approach to assess product sameness. A definitive screening design (DSD) was used to evaluate the impact of formulation and process variables. The formulation variables included drug percentage, percentage of corn oil and lanolin alcohol. The process variables studied were mixing temperature, mixing time and the method of mixing. The quality and performance attributes examined included drug assay, content uniformity, image analysis, rheology (storage modulus, shear viscosity) and in vitro drug release. Of the formulation variables evaluated, the percentage of the drug substance and the percentage of corn oil in the matrix were the most influential factors with respect to in vitro drug release. Conversely, the process parameters tested were observed to have minimal impact. An evaluation of the release mechanism of cyclosporine from the ointment revealed an interplay between formulation (e.g. physicochemical properties of the drug and ointment matrix type) and the release medium. These data provide a scientific basis to guide method development for in vitro drug release testing of ointment dosage forms. These results demonstrate that the in vitro methods used in this investigation were fit-for-purpose for detecting formulation and process changes and therefore amenable to assessment of product sameness.
1429 related Products with: Formulation Characteristics and In Vitro Release Testing of Cyclosporine Ophthalmic Ointments.
C Peptide ELISA Kit, Rat
Cultrex In Vitro Angiogen
Human integrin aVb3, affi
Inhibitory Mouse Monoclon
Inhibitory Mouse Monoclon
Resorufin Oleate, Fluorog
Multiple organ tumor tiss
Interleukin-34 IL34 (N-t
Interleukin-34 IL34 anti
Sterile filtered goat se
Sterile filtered goat se
Sterile filtered mouse s
Related Pathways





Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis.
Patients with severe atopic dermatitis (AD) may require potent immunosuppressive therapy to control their disease. Mycophenolate mofetil (MMF) has been suggested as a safe and effective drug in these cases. We have used oral MMF 2-3gr/day in adult patients with severe recalcitrant AD who failed other major systemic drugs, or where other drugs, including cyclosporine, methotrexate and azathioprine, were contraindicated. Of 9 consecutive adult patients, 4 (44%) responded completely, 2 (22%) had partial response and 3 (33%) did not respond at all. The MMF therapy was continued for 5-36 months (average 21 months) without major side effects. Our results demonstrate that oral MMF may be an effective drug in AD. Due to its good safety profile, it may be recommended as a first line systemic therapy, or successive to cyclosporine in the long term.
2368 related Products with: Mycophenolate mofetil therapy in adult patients with recalcitrant atopic dermatitis.
Disease State Samples: Si
Single Donor Human Atopic
Single Donor Human Atopic
Advanced Airway Intubatio
Syringe pump can be contr
Interleukin-34 IL34 (N-t
Interleukin-34 IL34 anti
Sterile filtered goat se
Sterile filtered goat se
Sterile filtered mouse s
Sterile filtered rat ser
ING1B antisense
Related Pathways





Unusual Case of Vogt-Koyanagi-Harada Disease Associated with SAPHO Syndrome: A Case Report.
A 66-year-old Japanese woman who was diagnosed with synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome presented with bilateral blurred vision 4 months prior to visiting our hospital. She had visited a local ophthalmology clinic first. She was diagnosed with conjunctivitis and was prescribed antibacterial eye drops. The symptoms persisted in spite of treatment. She was then referred to our hospital. At her initial visit, the visual acuities were 0.6 in both eyes. A slit-lamp examination revealed bilateral shallow anterior chamber, and intraocular pressures of 18 mm Hg in the right eye and 16 mm Hg in the left eye. There were no cells in the anterior chamber. Fundus examination revealed bilateral annular choroidal detachment and serous retinal detachment. Fluorescein angiography showed leakage of dye from the retinal pigment epithelium (RPE) and indocyanine green angiography showed focal choroidal hypoperfusion. Optical coherence tomography showed wavy RPE line and blurry thick choroid. Systemic investigation by the physician demonstrated bilateral pleural effusions of unknown origin. The patient had a past history of breast cancer; however, no metastasis was identified via malignant cells through cytology, laboratory findings, radiographs, CT, and MRI. After the diagnosis of Vogt-Koyanagi-Harada (VKH) disease was made, the patient was treated with local and systemic steroid including high-dose intravenous corticosteroids, and 150 mg of cyclosporine per day. Seventy days after the second high-dose of intravenous corticosteroids, these medications brought a complete resolution of both choroidal and retinal detachment. VKH disease associated with SAPHO syndrome is rare. The combination of immunosuppressive drug and steroid might be helpful for severe cases of VKH disease.
2093 related Products with: Unusual Case of Vogt-Koyanagi-Harada Disease Associated with SAPHO Syndrome: A Case Report.
Adrenal gland disease spe
Multiple organ diseased t
Multiple organ diseased t
Multiple organ normal and
Multiple organ normal and
Multiple organ normal and
Multiple organ normal and
Multiple organ diseased t
Tissue array of gastric d
Liver disease spectrum ti
Lung disease spectrum tis
Colon disease spectrum ti
Related Pathways





Epithelial to mesenchymal transition induces stem cell like phenotype in renal cell carcinoma cells.
Metastatic dissemination of solid tumors is often initiated by reactivation of an embryonic development program, epithelial-to-mesenchymal-transition (EMT). EMT has been associated with acquiring invasiveness and resistance to conventional therapies. However, the precise role of EMT during renal cell carcinoma is still debatable and is under investigation. In this context, our study is designed to evaluate the role of cyclosporine (CsA) and transforming growth factor-β (TGFβ) administration in inducing EMT-like state in renal carcinoma cells. We also studied the associated phenotypic changes which may lead to tumor metastasis.
2129 related Products with: Epithelial to mesenchymal transition induces stem cell like phenotype in renal cell carcinoma cells.
Macrophage Colony Stimula
Macrophage Colony Stimula
Rat Mesenchymal Stem Cell
anti HSV (II) gB IgG1 (mo
anti HCMV IE pp65 IgG1 (m
anti HCMV gB IgG1 (monocl
Cell Meterâ„¢ Fluorimetri
Cell Meterâ„¢ Fluorimetri
GLP 1 ELISA Kit, Rat Gluc
GLP 2 ELISA Kit, Rat Prog
Glucagon ELISA KIT, Rat G
Leptin ELISA Kit, Rat Lep
Related Pathways





Placebo Effects in the Immune System.
Even though knowledge and systematic application of placebo responses in the immune system are sparse, this topic is of particular importance since it may aim at drug-dose reduction while maintaining therapeutic efficacy of treatment in clinical settings. Placebo responses in the immune system are inducible by associated learning paradigms, such as behaviorally conditioned immunosuppression. One established learning paradigm in both rats and humans is conditioned taste avoidance (CTA), where a novel taste as conditioned stimulus (CS) is paired with the administration of the immunosuppressive drug cyclosporine A (CsA) as unconditioned stimulus. By representing the CS alone at a later time point, the conditioned response is reflected by avoidance behavior toward the taste (CTA). Simultaneously, diminished cytokine production and proliferative capacity of T cells are observed, closely mimicking the pharmacological effects of CsA. This chapter provides an overview on placebo responses in the immune system and delineates actual approaches, translational aspects, and limitations of learning paradigms in clinical settings.
2266 related Products with: Placebo Effects in the Immune System.
Thermal Shaker with cooli
Digestive system tissue a
Endocrine system benign,
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
Digestive system carcinom
Female reproductive syste
Multiple organ tumor tiss
Related Pathways





Association of time under immunosuppression and different immunosuppressive medication on periodontal parameters and selected bacteria of patients after solid organ transplantation.
Aim of this study was to investigate the association of the time under immunosuppression and different immunosuppressive medication on periodontal parameters and selected periodontal pathogenic bacteria of immunosuppressed patients after solid organ transplantation (SOT).
2921 related Products with: Association of time under immunosuppression and different immunosuppressive medication on periodontal parameters and selected bacteria of patients after solid organ transplantation.
Androgen Receptor (Phosph
Androgen Receptor (Phosph
Rabbit Anti-Human Androge
Rabbit Anti-Human Androge
Androgen Receptor (Ab 650
AZD-3514 Mechanisms: Andr
17β-Acetoxy-2α-bromo-5Î
(5α,16β)-N-Acetyl-16-[2
(5α,16β)-N-Acetyl-16-ac
5α-N-Acetyl-2'H-androst-
5α-N-Acetyl-2'H-androst-
3-O-Acetyl 5,14-Androstad
Related Pathways





Improving the utility of clinical phenotyping in interstitial cystitis/painful bladder syndrome: from UPOINT to INPUT.
The phenotyping system UPOINT has proven effective in classifying patients with Urologic Pelvic Pain Syndromes in a clinically meaningful way and to guide therapy. While highly successful in men with chronic pelvic pain syndrome (CPPS), UPOINT is more limited in patients with interstitial cystitis/painful bladder syndrome (IC/PBS) since by definition all patients have the urinary and organ specific phenotype. Furthermore, AUA guidelines recommend a sequential tiered approach to therapy rather than the multimodal UPOINT scheme. We sought to modify UPOINT to be more practical and efficacious for IC/PBS.
1621 related Products with: Improving the utility of clinical phenotyping in interstitial cystitis/painful bladder syndrome: from UPOINT to INPUT.
Bladder cancer tissue arr
Bladder cancer tissue arr
Bladder cancer tissue arr
Mid advanced stage bladde
Bladder cancer tissue arr
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
Multiple organ tumor tiss
Oral squamous cell cancer
Bladder cancer test tissu
Related Pathways





Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study.
The lack of high-quality clinical evidences hindered broad consensus on optimal therapies for primary nephrotic syndromes. The aim of the present study was to compare prevalence of immunosuppressive drug use in patients with primary nephrotic syndrome across 6 regions in Japan.
1897 related Products with: Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study.
Goat Anti-Human Wiskott-A
Primary antibody FLIP An
Thermal Shaker with cooli
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
FDA Standard Frozen Tissu
Multiple organ tumor tiss
Syringe pump can be contr
MultiGene Gradient therm
Related Pathways





Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis.
Cyclosporine (CsA) is a substrate of cytochrome P450 (CYP) 3A4 with a narrow therapeutic index and large individual difference. CYP3A4*1B is reported to be associated with CsA pharmacokinetics parameters, but the relevance is still in dispute. Therefore, a meta-analysis was employed to evaluate the influence of CYP3A4*1B on CsA pharmacokinetics at different post-transplantation times in adult renal transplant recipients.
2433 related Products with: Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis.
HCV core 2 119aa recombin
HCV NS3 1192 1456aa recom
HCV NS3 1359 1456aa antig
HCV NS5 2212 2313aa recom
Mouse Anti-Human Interleu
Mouse Anti-Human Interleu
Mouse Anti-Human Interleu
Mouse Anti-Human Interleu
Recombinant Human Interfe
Recombinant Human Interfe
Goat Anti- CYP3A4, (inter
Goat Anti-Mouse, Rat Rena
Related Pathways





Psoriasis Management in Actual Clinical Practice: A 6-Year Retrospective Study of 845 Patients.
Over the past years, with the availability of relatively well tolerated, very effective but expensive drugs, biologics, treatment of psoriasis has dramatically shifted from inpatient modalities to outpatient ones. Relatively little is known about true life practices regarding psoriasis treatment in our country.
1647 related Products with: Psoriasis Management in Actual Clinical Practice: A 6-Year Retrospective Study of 845 Patients.
Multi organ carcinoma tis
Multi organ carcinoma tis
Pancreatic carcinoma and
Multiple organs tumor and
Tissue array of gastric d
Multiple organ cancer tis
Stomach adenocarcinoma wi
Liver disease spectrum ti
Liver carcinoma and norma
Liver carcinoma and norma
Liver carcinoma and norma
Lung disease spectrum tis
Related Pathways
Contact Us:
Belgium
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
info@gentaur.com
France
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
france@gentaur.com
Germany
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
de@gentaur.com
United Kingdom
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com
Also in
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
Poland
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
poland@gentaur.com
skype gentaurpoland
Nederland
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
nl@gentaur.com
Italy
GENTAUR SRL
IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
italia@gentaur.com
Spain
GENTAUR Spain
Tel 0911876558
spain@gentaur.com
Bulgaria
GENTAUR Bulgaria
53 Iskar Str. 1191 Kokalyane, Sofia
Sofia 1000
Tel 0035924682280
Fax 0035929830072
sofia@gentaur.com